Non-Muscle Invasive Bladder Cancer: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| Line 486: | Line 486: | ||
*# '''<span style="color:#ff0000">Intravesical nadofaragene firadenovec''' | *# '''<span style="color:#ff0000">Intravesical nadofaragene firadenovec''' | ||
*# '''<span style="color:#ff0000">BCG plus N-803''' | *# '''<span style="color:#ff0000">BCG plus N-803''' | ||
*# '''<span style="color:#ff0000">Valrubicin[https://pubmed.ncbi.nlm.nih.gov/38265030/]''' | |||
** Chemoradiation should not be recommended for patients with BCG-unresponsive CIS | ** Chemoradiation should not be recommended for patients with BCG-unresponsive CIS | ||
* '''<span style="color:#ff0000">BCG-unresponsive who are unfit for or refuse to undergo radical cystectomy[https://pubmed.ncbi.nlm.nih.gov/33938798/]''' | * '''<span style="color:#ff0000">BCG-unresponsive who are unfit for or refuse to undergo radical cystectomy[https://pubmed.ncbi.nlm.nih.gov/33938798/]''' | ||